The board of Royalty Pharma plc ( NASDAQ:RPRX ) has announced that the dividend on 10th of March will be increased ...

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an ...

Teva and Royalty Pharma have signed a deal worth up to $500 million to advance TEV-408, a drug being tested for vitiligo and ...

Teva has penned a second pact with Royalty Pharma, this time securing up to $500 million to support the clinical development ...

Royalty Pharma plc operates a diversified royalty portfolio while appearing in broader discussions tied to the nasdaq 100 ...

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million, to support Teva's anti-IL-15 candidate, TEV-'408 TE ...

Royalty Pharma and the US affiliate of Israel’s Teva Pharmaceutical Industries have announced a funding agreement of up to ...

The total market size of systemic lupus erythematosus is expected to increase in the 7MM during the forecast period, driven by ongoing clinical research of therapies such as nipocalimab (Johnson & ...

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million to support Teva's anti-IL-15 candidate TEV-'408TEV-' ...

Royalty Pharma's board has raised the biopharmaceutical royalties investor's quarterly dividend by 6.8%, to 23.5 cents from 22 cents. The new payout, equal to 94 cents a year, represents an annual ...

Teva Pharmaceutical Industries (TASE: TEVA; NYSE: TEVA) published two positive announcements yesterday. The first concerns ...

Teva Pharmaceuticals TEVA announced a funding agreement with Royalty Pharma plc RPRX, under which the latter will provide up ...